Summary by Moomoo AI
On June 20th, 2024, SciClone Pharmaceuticals-B (02171.HK) submitted a disclosure report for the following day, revealing its share buyback situation. According to the report, the company repurchased 1,100,000 ordinary shares on June 20th, 2024, with a purchase price ranging from HKD 5.61 to HKD 5.88 per share, for a total price of HKD 6,373,810. This share buyback was carried out under the repurchase authorization obtained by the company on May 21st, 2024, which allows the company to repurchase up to 57,564,391 shares. As of June 20th, 2024, the company has cumulatively repurchased 3,840,000 shares, accounting for 0.667% of the repurchase authorization. The company confirmed that all repurchases were carried out in accordance with the Listing Rules, laws and other regulatory requirements of the Hong Kong Stock Exchange, and had obtained formal authorization and approval from the board of directors. In addition, the company will suspend any new stock issuances or inventory share resales or transfers within 30 days after the share repurchase, that is, until July 20th, 2024.